MAPK14

(redirected from p38 MAP kinase)

MAPK14

A gene on chromosome 6p21.3-p21.2 that encodes a member of the MAP kinase family, which integrate multiple biochemical signals and are involved in cell proliferation, differentiation, transcription, regulation and development. MAPK14 is phosphorylated and activated by MAP kinases or autophosphorylated by interaction with MAP3K7IP1/TAB1 protein.

MAPK14 substrates
Transcription regulator ATF2, cell cycle regulator CDC25B and tumour suppressor p53, suggesting that MAPK14 has a role in stress-related transcription and cell cycle regulation, as well as in
genotoxic stress response.
References in periodicals archive ?
LATITUDE-TIMI 60 (LosmApimod To Inhibit p38 MAP kinase as aTherapeUtic target and moDify outcomes after an acute coronary syndrome-Thrombolysis In Myocardial Infarction 60; NCT02145468) was a randomised, double-blind, placebo-controlled, multi-centre study across 39 countries.
To further examine the role of p38 MAP kinase on the regulation of survivin, we incubated cells with 10 [micro]M of TIIA in the presence of SB203580 to investigate whether p38 MAPK was involved in the TIIA-induced downregulation of survivin expression.
Study 302: "A clinical study of two doses of a selective p38 MAP kinase inhibitor, VX-745, to evaluate the effects of 12-Week oral twice-daily dosing on amyloid plaque load as assessed by Quantitative Dynamic 11C-PiB positive emission tomography (PET) amyloid scanning".
The researchers found that many muscle stem cells isolated from mice that were 2 years old, equivalent to about 80 years of human life, exhibited elevated levels of activity in a biological cascade called the p38 MAP kinase pathway.
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase.
Four partnered programs are in active clinical trials: a CXCR2 antagonist for chronic obstructive pulmonary disease, p38 MAP kinase inhibitors for rheumatoid arthritis, an enzyme inhibitor for oncology and a candidate for metabolic diseases.
ARRY-797 is a selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy in preclinical models of human, the company said.
And this raises the dazzling possibility that a class of drugs now in development--the p38 MAP kinase inhibitors--could play a role in the treatment of each of the diseases in this eclectic group, Dr.
The company is developing two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage osteoarthritis patients.
6add45a regulates matrix metalloproteinases by suppressing DeltaNp63[alpha] and [beta]-catenin via p38 MAP kinase and APC complex activation.
Oral Presentation (ERS 2011 Abstract #4499): "Inhaled Calcium Salts Reduce Tobacco Smoke-Induced Airway Inflammation and Improve Lung Pathology:" In a mouse model of acute tobacco smoke-induced airway inflammation, PUR118 reduced inflammation and improved lung pathology with equivalent efficacy to the positive control, a p38 MAP kinase inhibitor.